Alexander Karaskov

Alexander Karaskov

Auto-generated profile, based on publicly available information

Alexander Karaskov

E. N. Meshalkin National Medical Research Center of the Ministry of Health

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in JACC
Verified
Journal Article
Closed access
EPEvgeny Pokushalov
Evgeny Pokushalov
ARAlexander Romanov
Alexander Romanov
GCGiorgio Corbucci
Giorgio Corbucci
SASergey Artyomenko
Sergey Artyomenko
VBVera Baranova
Vera Baranova
JSJonathan S. Steinberg
Jonathan S. Steinberg

1 December 2015 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
PDF file
EPEvgeny Pokushalov
Evgeny Pokushalov
BKBoris Kozlov
Boris Kozlov
ARAlexander Romanov
Alexander Romanov
ASArtem Strelnikov
Artem Strelnikov
SBSevda Bayramova
Sevda Bayramova
JSJonathan S. Steinberg
Jonathan S. Steinberg
Background—: Animal models suggest that the neurotransmitter inhibitor, botulinum toxin, when injected into the epicardial fat pads can suppress atrial fibrillation inducibility. The aim of this prospective randomized double-blind study was to compare the efficacy and safety of botulinum toxin injection into epicardial fat pads for preventing atrial tachyarrhythmias. Methods and Results—: Patients with history of paroxysmal atrial fibrillation and indication for coronary artery bypass graft surgery were randomized to botulinum toxin (Xeomin, Merz, Germany; 50 U/1 mL at each fat pad; n=30) or placebo (0.9% normal saline, 1 mL at each fat pad; n=30) injection into epicardial fat pads during surgery. Patients were followed for 1 year to assess maintenance of sinus rhythm using an implantable loop recorder. All patients in both groups had successful epicardial fat pad injections without complications. The incidence of early postoperative atrial fibrillation within 30 days after coronary artery bypass graft was 2 of 30 patients (7%) in the botulinum toxin group and 9 of 30 patients (30%) in the placebo group ( P =0.024). Between 30 days and up to the 12-month follow-up examination, 7 of the 30 patients in the placebo group (27%) and none of the 30 patients in the botulinum toxin group (0%) had recurrent atrial fibrillation ( P =0.002). There were no complications observed during the 1-year follow-up. Conclusions—: Botulinum toxin injection into epicardial fat pads during coronary artery bypass graft provided substantial atrial tachyarrhythmia suppression both early as well as during 1-year follow-up, without any serious adverse events. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01842529.

1 July 2014 in Heart Rhythm
Verified
Journal Article
Closed access
EPEvgeny Pokushalov
Evgeny Pokushalov
ARAlexander Romanov
Alexander Romanov
DKDemosthenes G. Katritsis
Demosthenes G. Katritsis
SASergey Artyomenko
Sergey Artyomenko
SBSevda Bayramova
Sevda Bayramova
JSJonathan S. Steinberg
Jonathan S. Steinberg

11 October 2010 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
EPEvgeny Pokushalov
Evgeny Pokushalov
ARAlexander Romanov
Alexander Romanov
GCGiorgio Corbucci
Giorgio Corbucci
SASergey Artyomenko
Sergey Artyomenko
ATAlex Turov
Alex Turov
AKAlexander Karaskov
Alexander Karaskov

1 December 2011 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
EPEvgeny Pokushalov
Evgeny Pokushalov
ARAlexander Romanov
Alexander Romanov
GCGiorgio Corbucci
Giorgio Corbucci
SASergey Artyomenko
Sergey Artyomenko
ATAlex Turov
Alex Turov
AKAlexander Karaskov
Alexander Karaskov
Background—: Catheter ablation of atrial fibrillation (AF) has proved effective in curing highly symptomatic patients with paroxysmal AF. The aim of this prospective, randomized study was to identify the optimal treatment of patients with AF recurrences after the first ablation. Methods and Results—: Two hundred eighty-six patients with paroxysmal AF underwent ablation (circumferential pulmonary vein isolation with linear lesions) and were monitored with an implantable cardiac monitor (Reveal XT, Medtronic). Patients without AF recurrences during the 3-month postablation period were assigned to group 1; those with AF recurrences to group 2. Patients in group 2 were randomly assigned to group 3 or group 4. Group 3 patients were treated only with antiarrhythmic drugs for 6 weeks, with no early reablation during the 3-month postablation period. In the case of AF recurrence after the 3-month postablation period, patients underwent reablation. Group 4 patients were treated according to the onset mechanism of AF recurrences, as detected and stored by the implantable cardiac monitor: antiarrhythmic drug therapy, but no reablation if AF was not preceded by triggers; early reablation if premature atrial beats or atrial tachycardias or flutter triggered AF. All patients were followed up for 1 year to assess maintenance of sinus rhythm in each group. On 12-month follow-up examination, of the 119 (42%) patients in group 1, 112 (94%) had no AF recurrences. Among the 83 patients in group 3, only 27 (33%) had no recurrences. Of the 84 group 4 patients, 67 (80%) had no AF recurrences ( P <0.0001 versus group 3). Conclusions—: Patients with recurrences after the first AF ablation are likely to respond to a second early ablation when AF is triggered by supraventricular arrhythmias or premature contractions. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01164319.

1 August 2014 in JACC
Verified
Journal Article
Closed access
EPEvgeny Pokushalov
Evgeny Pokushalov
BKBoris Kozlov
Boris Kozlov
ARAlexander Romanov
Alexander Romanov
ASArtem Strelnikov
Artem Strelnikov
SBSevda Bayramova
Sevda Bayramova
JSJonathan S. Steinberg
Jonathan S. Steinberg